Sirukumab Terminated Phase 3 Trials for Giant Cell Arteritis (GCA) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02531633Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis